These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
86 related articles for article (PubMed ID: 291484)
1. Phase II study of cis-dichlorodiammineplatinum(II) in childhood osteosarcoma: Children's Cancer Study Group Report. Baum ES; Gaynon P; Greenberg L; Krivit W; Hammond D Cancer Treat Rep; 1979; 63(9-10):1621-7. PubMed ID: 291484 [No Abstract] [Full Text] [Related]
2. cis-Dichlorodiammineplatinum(II) in childhood cancer. Freeman AI; Ettinger LJ; Brecher ML Cancer Treat Rep; 1979; 63(9-10):1615-20. PubMed ID: 291483 [TBL] [Abstract][Full Text] [Related]
3. cis-Dichlorodiammineplatinum (II) in small cell anaplastic bronchogenic carcinoma: a phase II study. Dombernowsky P; Sörenson S; Aisner J; Hansen HH Cancer Treat Rep; 1979 Apr; 63(4):543-5. PubMed ID: 221119 [No Abstract] [Full Text] [Related]
4. cis-Dichlorodiammineplatinum(II) in the treatment of gynecologic malignancies: phase II trials by the Gynecologic Oncology Group. Thigpen T; Shingleton H; Homesley H; LaGasse L; Blessing J Cancer Treat Rep; 1979; 63(9-10):1549-55. PubMed ID: 498154 [TBL] [Abstract][Full Text] [Related]
5. [Cis-dichlorodiammineplatinum in osteosarcoma. Osteosarcoma Cooperative Study Group report]. Fukuma H; Beppu Y; Chuman H; Yagi T; Yamawaki S; Isu K; Funayama K; Tanuma M; Abe Y; Toriyama S Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 1):811-7. PubMed ID: 2653222 [TBL] [Abstract][Full Text] [Related]
6. Phase II evaluation of cis-dichlorodiammineplatinum(II) in advanced malignancies of the genitourinary and gynecologic organs: a Southwest Oncology Group Study. Rossof AH; Talley RW; Stephens R; Thigpen T; Samson MK; Groppe C; Eyre HJ; Fisher R Cancer Treat Rep; 1979; 63(9-10):1557-64. PubMed ID: 498155 [TBL] [Abstract][Full Text] [Related]
8. Phase II evaluation of cis-dichlorodiammineplatinum(II) in lymphomas: a Southwest Oncology Group Study. Rossof AH; Coltman CA; Jones SE; Talley RW Cancer Treat Rep; 1979; 63(9-10):1605-8. PubMed ID: 498159 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of cis-dichlorodiammineplatinum(II) in children with advanced malignant diseases: Southwest Oncology Group Studies. Vietti TJ; Nitschke R; Starling KA; van Eys J Cancer Treat Rep; 1979; 63(9-10):1611-4. PubMed ID: 291482 [TBL] [Abstract][Full Text] [Related]
10. Phase II study of cisplatin in advanced osteogenic sarcoma. European Organization for Research on Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Gasparini M; Rouesse J; van Oosterom A; Wagener T; Somers R; Russel JA; Voûte PA; Bramwell V; Thomas D; Sylvester R Cancer Treat Rep; 1985 Feb; 69(2):211-3. PubMed ID: 3855699 [TBL] [Abstract][Full Text] [Related]
11. Phase II trail cisplatin in refractory childhood cancer: Children's Cancer Study Group Report. Baum ES; Gaynon P; Greenberg L; Krivit W; Hammond D Cancer Treat Rep; 1981; 65(9-10):815-22. PubMed ID: 6944156 [TBL] [Abstract][Full Text] [Related]
12. Tetany: a complication of cis-dichlorodiammineplatinum(II) therapy. Hayes FA; Green AA; Senzer N; Pratt CB Cancer Treat Rep; 1979 Apr; 63(4):547-8. PubMed ID: 445508 [No Abstract] [Full Text] [Related]
13. cis-Dichlorodiammineplatinum(II) for the treatment of advanced ovarian cancer. Young RC; Von Hoff DD; Gormley P; Makuch R; Cassidy J; Howser D; Bull JM Cancer Treat Rep; 1979; 63(9-10):1539-44. PubMed ID: 387224 [TBL] [Abstract][Full Text] [Related]
14. [A clinical study of intraarterial infusion therapy with CDDP for primary osteosarcoma]. Eiro I; Kobayashi H; Uchiyama N; Itoh Y; Shinohara S; Itoh H; Morimoto N; Sakoh T Gan To Kagaku Ryoho; 1990 Jan; 17(1):47-52. PubMed ID: 2297238 [TBL] [Abstract][Full Text] [Related]
15. Phase II study of ICRF-159 versus combination cis-dichlorodiammineplatinum(II) and DTIC in patients with disseminated malignant melanoma. Ahmann DL; Edmonson JH; Frytak S; Kvols LK; Bisel HF; Rubin J Cancer Treat Rep; 1978 Jan; 62(1):151-3. PubMed ID: 626995 [No Abstract] [Full Text] [Related]
16. Ifosfamide tolerance in osteosarcoma patients previously treated with cis-diamminedichloroplatinum-II: renal, hematologic, and neurologic observations. Canpolat C; Pearson P; Robertson R; Jaffe N Med Pediatr Oncol; 1996 Jan; 26(1):36-47. PubMed ID: 7494510 [TBL] [Abstract][Full Text] [Related]
17. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group. Meyers PA; Schwartz CL; Krailo MD; Healey JH; Bernstein ML; Betcher D; Ferguson WS; Gebhardt MC; Goorin AM; Harris M; Kleinerman E; Link MP; Nadel H; Nieder M; Siegal GP; Weiner MA; Wells RJ; Womer RB; Grier HE; J Clin Oncol; 2008 Feb; 26(4):633-8. PubMed ID: 18235123 [TBL] [Abstract][Full Text] [Related]
18. Phase II trial of cis-dichlorodiammineplatinum(II) in cancer of the bilharzial bladder. Gad-el-Mawla N; Chevlen E; Hamza R; Ziegler JL Cancer Treat Rep; 1979; 63(9-10):1577-8. PubMed ID: 498157 [No Abstract] [Full Text] [Related]
19. Phase II study of high-dose cis-dichlorodiammineplatinum(II) in the treatment of non-small cell lung cancer. Casper ES; Gralla RJ; Kelsen DP; Cvitkovic E; Golbey RB Cancer Treat Rep; 1979; 63(11-12):2107-9. PubMed ID: 575068 [No Abstract] [Full Text] [Related]
20. Cis-dichlorodiammineplatinum(II) in advanced soft tissue and bony sarcomas: a Southwest Oncology Group Study. Samson MK; Baker LH; Benjamin RS; Lane M; Plager C Cancer Treat Rep; 1979; 63(11-12):2027-9. PubMed ID: 575067 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]